Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093)

Mark A. Jacobson*, Michael Wulfsohn, Judith E. Feinbergt, Roger Davis, Maureen Power, Susan Owens, Dennis Causey, Margo E. Heath-Chiozzi, Robert L. Murphy, Tony W. Cheung, Douglas T. Dieterich, Stephen A. Spector, George F. McKinley, David M. Parenti, Clyde Crumpacker

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093)'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS